GEHC

ACCE-researched
GE HealthCare Technologies Inc. Common Stock
Healthcare · Medical Devices · NASDAQ · United States
$64.13-0.49%
Market cap $29.0BNext earnings 2026-11-04Updated Sep 20, 2026
FAIR VALUE · CONSENSUS
$64.13+0.0%
confidence-weighted across 4 of 6 models
Now $64.13
$64.13
$48.38$115.12
BuyBronze50
Price vs fair value
14.0% below
+16.3% to fair value
ACCE score
58
out of 100
Analysts
76% buy
21 covering
P/E
14.8x
forward 11.8x
1-year return
-13.3%
Dividend yield
0.22%
Unlock the ACCE read
INVESTOR

Overview

⚠ Investor warnings · 3 flags
  • high
    QoQ revenue decline
    Revenue dropped 10.0% quarter-over-quarter, indicating potential business momentum issues.
  • moderate
    Earnings miss
    Q1 2026 EPS came in 5.7% below expectations, missing analyst forecasts.
  • moderate
    Low growth score
    ACCE growth score of only 28/100 suggests weak fundamental growth metrics.
Reports in 44 days, last quarter beat by 0.1%.

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Price

-14.2% · 1Y

Valuation

INVESTOR
Full valuation engine INVESTOR FEATURE

Six independent models converge on one confidence-weighted fair value, with full methodology and editable assumptions.

  • +All six models: DCF, P/E and EV/EBITDA comps, Graham, dividend discount, residual income
  • +Scenario bands, sensitivity tornado, and the 5-year historical valuation range
  • +Editable DCF workbench with saved scenarios

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: conviction breakdown, earnings quality, score history, and backtested returns.

  • +Conviction score breakdown and earnings-quality grade
  • +Growth / value / quality / momentum component scores
  • +90-day score history and score-threshold backtests

Analysts

Wall Street consensus

Bullish76% buy · 21 covering analysts
● Strong buy 12● Buy 4● Hold 5● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO
Smart money tracking PRO FEATURE

Follow the institutions: 13F position changes, insider trades, and active 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Recent open-market insider transactions
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

This stock Peer Peer median weaker → stronger
P/Ebetter than 100% of peers
low 14.8x14.8xhigh 35.3x
ROEbetter than 83% of peers
low 6%19%high 38%
Div yieldbetter than 17% of peers
low 0.0%0.2%high 4.1%

Algorithmic peers (6)

TickerCompanyMcapP/EROED/EYieldQuality
DXCMDexCom Inc. Common Stock$33.7B35.338.5%0.460.0%-Compare
PHIA.ASKoninklijke Philips$24.2B18.910.2%0.624.0%-Compare
PHGKoninklijke Philips N.V. NY Registry Shares$24.1B18.810.2%0.714.1%-Compare
4543.TTerumo$20.9B24.310.9%26.361.6%-Compare
STESTERIS plc (Ireland) Ordinary Shares$20.0B25.111.4%0.271.2%-Compare
ZBHZimmer Biomet Holdings Inc. Common Stock$18.2B23.16.4%0.591.0%-Compare

Sector report card

Where GEHC ranks against its sector peers on each metric.

Computing percentiles…

News and Record

Reports in 44 days, last quarter beat by 0.1%.

Press releases mentioning this company

Ask anything, Pro feature

Ask questions about this stock in plain language. Answered from company fundamentals + recent valuations.

PRO

Recent performance

1 week
+0.3%
1 month
-14.1%
3 months
+4.1%
6 months
-7.9%
YTD
-21.8%
1 year
-13.3%

SEC filings

40 filings
September 2026
Sep 16
Form 4Insider transactionPeriod 2026-09-14
Sep 4
Form 4Insider transactionPeriod 2026-09-03
Sep 4
Form 4Insider transactionPeriod 2026-09-03
37 more filings + AI summaries on Investor+.INVESTOR